A detailed history of Robeco Institutional Asset Management B.V. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Robeco Institutional Asset Management B.V. holds 73,568 shares of ALNY stock, worth $18.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
73,568
Previous 49,670 48.11%
Holding current value
$18.1 Million
Previous $12.1 Million 67.68%
% of portfolio
0.04%
Previous 0.03%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$233.81 - $287.01 $5.59 Million - $6.86 Million
23,898 Added 48.11%
73,568 $20.2 Million
Q2 2024

Jul 22, 2024

BUY
$143.31 - $247.0 $2.99 Million - $5.15 Million
20,830 Added 72.23%
49,670 $12.1 Million
Q1 2024

Apr 24, 2024

BUY
$146.51 - $198.2 $689,329 - $932,531
4,705 Added 19.49%
28,840 $4.31 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $542,956 - $704,900
3,586 Added 17.45%
24,135 $4.62 Million
Q4 2023

Feb 08, 2024

BUY
$151.41 - $196.57 $1.89 Million - $2.46 Million
12,513 Added 155.71%
20,549 $24.1 Million
Q3 2023

Oct 23, 2023

SELL
$170.77 - $211.65 $3.26 Million - $4.04 Million
-19,107 Reduced 70.39%
8,036 $1.42 Million
Q2 2023

Jul 24, 2023

SELL
$185.01 - $212.05 $4.74 Million - $5.43 Million
-25,615 Reduced 48.55%
27,143 $5.16 Million
Q1 2023

May 03, 2023

BUY
$182.66 - $235.53 $140,830 - $181,593
771 Added 1.48%
52,758 $10.6 Million
Q4 2022

Feb 06, 2023

BUY
$185.53 - $241.31 $2.34 Million - $3.05 Million
12,628 Added 32.08%
51,987 $12.4 Million
Q3 2022

Dec 01, 2022

BUY
$138.54 - $232.0 $5.12 Million - $8.57 Million
36,948 Added 1532.48%
39,359 $7.88 Million
Q3 2022

Oct 26, 2022

BUY
$138.54 - $232.0 $5.12 Million - $8.57 Million
36,948 Added 1532.48%
39,359 $7.88 Million
Q2 2022

Dec 01, 2022

SELL
$120.42 - $169.29 $69,723 - $98,018
-579 Reduced 19.36%
2,411 $352,000
Q2 2022

Jul 27, 2022

SELL
$120.42 - $169.29 $69,723 - $98,018
-579 Reduced 19.36%
2,411 $352,000
Q1 2022

Dec 01, 2022

BUY
$127.18 - $173.91 $375,308 - $513,208
2,951 Added 7566.67%
2,990 $488,000
Q1 2022

Apr 26, 2022

BUY
$127.18 - $173.91 $375,308 - $513,208
2,951 Added 7566.67%
2,990 $488,000
Q4 2021

Dec 01, 2022

SELL
$159.56 - $209.29 $568,512 - $745,700
-3,563 Reduced 98.92%
39 $7,000
Q4 2021

Jan 31, 2022

BUY
$159.56 - $209.29 $6,222 - $8,162
39 New
39 $7,000
Q3 2021

Oct 20, 2021

SELL
$169.75 - $207.73 $611,439 - $748,243
-3,602 Closed
0 $0
Q2 2021

Dec 01, 2022

SELL
$128.63 - $176.89 $669,905 - $921,243
-5,208 Reduced 59.11%
3,602 $611,000
Q2 2021

Jul 28, 2021

SELL
$128.63 - $176.89 $669,905 - $921,243
-5,208 Reduced 59.11%
3,602 $611,000
Q1 2021

Dec 01, 2022

SELL
$126.83 - $175.69 $3.87 Million - $5.37 Million
-30,549 Reduced 77.62%
8,810 $1.24 Million
Q1 2021

Apr 23, 2021

SELL
$126.83 - $175.69 $690,462 - $956,456
-5,444 Reduced 38.19%
8,810 $1.24 Million
Q4 2020

Dec 01, 2022

SELL
$122.97 - $147.0 $3.09 Million - $3.69 Million
-25,105 Reduced 63.78%
14,254 $1.85 Million
Q4 2020

Jan 28, 2021

SELL
$122.97 - $147.0 $2.53 Million - $3.03 Million
-20,599 Reduced 59.1%
14,254 $1.85 Million
Q3 2020

Oct 29, 2020

SELL
$121.19 - $165.49 $3.09 Million - $4.23 Million
-25,534 Reduced 42.28%
34,853 $5.07 Million
Q2 2020

Jul 20, 2020

BUY
$104.21 - $156.44 $6.03 Million - $9.05 Million
57,870 Added 2299.17%
60,387 $8.94 Million
Q1 2020

Apr 30, 2020

BUY
$93.12 - $133.99 $234,383 - $337,252
2,517 New
2,517 $273,000
Q4 2018

Feb 08, 2019

SELL
$62.67 - $88.33 $89,430 - $126,046
-1,427 Closed
0 $0
Q3 2018

Oct 31, 2018

SELL
$87.52 - $122.67 $124,891 - $175,050
-1,427 Reduced 50.0%
1,427 $125,000
Q3 2018

Oct 25, 2018

BUY
$87.52 - $122.67 $124,891 - $175,050
1,427 Added 100.0%
2,854 $266,000
Q1 2018

May 07, 2018

BUY
$115.92 - $148.54 $165,417 - $211,966
1,427 New
1,427 $170,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.2B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Robeco Institutional Asset Management B.V. Portfolio

Follow Robeco Institutional Asset Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Robeco Institutional Asset Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Robeco Institutional Asset Management B.V. with notifications on news.